Health CarePharmaceuticals and Biotechnology
  • Price (EUR)47.00
  • Today's Change-0.600 / -1.26%
  • Shares traded1.98k
  • 1 Year change+8.55%
  • Beta0.5677
Data delayed at least 15 minutes, as of Aug 19 2022 14:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

  • Revenue in EUR (TTM)455.20m
  • Net income in EUR28.56m
  • Incorporated1967
  • Employees2.77k
  • Location
    Boiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
  • Phone+33 478456100
  • Fax+33 478456291
  • Websitehttp://www.boiron.fr/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BOI:PAR since
Abbi SasDeal completed20 Jan 202220 Jan 2022Deal completed29.66%1.98m
Data delayed at least 15 minutes, as of Aug 19 2022 14:01 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eurobio Scientific SA184.71m60.54m214.84m165.003.401.333.121.155.535.5316.9014.170.96675.653.851,119,467.0031.6924.1340.6234.4655.3550.5232.7823.664.3672.290.09240.00-2.1946.13-17.61--55.99--
Innate Pharma SA12.11m-45.48m215.02m215.00--2.03--18.03-0.572-0.66340.15231.350.0421--2.1256,334.88-15.82-6.65-20.23-9.5874.6992.81-375.48-45.00----0.4407---78.43-26.42-5,385.89---32.35--
Transgene SA17.01m-19.54m217.44m167.00--3.20--12.96-0.219-0.2190.18670.68740.1817--2.88101,880.20-20.86-15.27-24.56-18.27-----114.82-147.28----0.0541--82.1014.28-13.38--90.14--
Genfit SA85.58m67.26m221.58m112.004.211.883.202.621.071.071.542.390.3563367.75201.84764,098.2028.01-18.6734.81-21.8298.2893.3978.59-157.664.27--0.3735--1,003.1166.03166.45---23.40--
Guerbet SA732.07m32.64m257.88m2.73k7.960.64072.930.35492.582.5857.8732.080.75220.93936.37268,157.903.353.624.325.0473.9275.554.464.701.246.050.451627.452.78-1.1578.932.44-0.34430.00
Carbios SA105.00k3.78m339.34m59.0089.142.3845.573,323.390.350.350.009613.130.0009--0.97671,779.664.14-5.464.44-5.96-701.90--4,675.24-316.96--10.900.0844---17.97-58.82145.69-5.14107.86--
AB Science SA1.61m-14.46m370.19m98.00------233.86-0.3029-0.30290.0338-0.43630.06311.014.8316,397.96-56.76-69.55-265.60-203.8993.0991.10-899.94-1,273.481.03-321.12----1.521.283.87--1.48--
DBV Technologies SA5.54m-95.22m482.04m226.00------86.37-1.74-1.740.1012-----------------------1,717.80-1,272.93---586.89-----49.38-10.6938.59------
Boiron SA455.20m28.56m833.41m2.77k28.901.5519.521.821.631.6325.9930.360.58641.504.89164,391.803.685.964.697.5071.9776.846.278.412.32--0.023246.86-11.37-5.828.95-18.15-10.06-9.90
Valneva SE346.72m-71.76m1.19bn722.00--7.3856.383.44-0.7206-0.72063.421.380.5131.5813.82480,218.80-10.62-8.98-21.48-12.9246.0353.98-20.70-18.411.12-2.630.4377--215.5229.91-14.03--90.83--
Vetoquinol SA521.27m62.86m1.45bn2.55k23.333.3216.292.835.315.3144.0737.300.82052.615.93204,741.609.886.9714.359.1850.6861.1012.048.781.03--0.033715.1521.948.27227.0417.7018.9713.22
Euroapi SAS-100.00bn-100.00bn1.53bn3.34k-------------------------------------------------5.48---150.79------
Virbac SA1.06bn113.16m3.10bn5.10k27.434.2819.572.9213.4013.40125.9585.820.92082.3210.18207,805.7010.005.2614.497.5447.5047.4610.867.100.955720.290.11535.3113.894.06-16.8226.713.33--
Data as of Aug 19 2022. Currency figures normalised to Boiron SA's reporting currency: Euro EUR

Institutional shareholders

13.01%Per cent of shares held by top holders
HolderShares% Held
Natixis Investment Managers International SAas of 31 Dec 20211.01m5.78%
Financi�re de l'�chiquier SAas of 31 Dec 2021439.37k2.50%
Sycomore Asset Management SAas of 30 Sep 2021199.93k1.14%
Amiral Gestion SAas of 31 Dec 2021140.99k0.80%
BlackRock Fund Advisorsas of 03 Aug 2022106.52k0.61%
Dimensional Fund Advisors LPas of 04 Aug 202296.59k0.55%
Norges Bank Investment Managementas of 31 Dec 202183.48k0.48%
The Vanguard Group, Inc.as of 05 Aug 202278.53k0.45%
SMA Gestion SAas of 30 Jun 202176.17k0.43%
Gay-Lussac Gestion SAas of 31 Dec 202147.50k0.27%
More ▼
Data from 30 Jun 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.